<p>aTyr Pharma, Inc. (NASDAQ:ATYR - 获取免费报告) 在 12 月份经历了显著的空头头寸下降。截至 12 月 31 日，空头头寸总计为 25,013,857 股，比 12 月 15 日的 30,385,566 股下降了 17.7%。根据平均每日交易量 2,246,751 股，目前的空头头寸比率为 11.1 天。大约 26.5% 的公司股份被做空。</p>
<h2>对 aTyr Pharma 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近调整了对该股票的持有。加利福尼亚州教师退休系统在第二季度购买了 aTyr Pharma 的新头寸，价值约 28,000 美元。Ameritas Investment Partners Inc.在第二季度购买了 aTyr Pharma 的股份，价值约 45,000 美元。Legal &amp; General Group Plc 在第二季度购买了 aTyr Pharma 的股份，价值约 49,000 美元。Prudential Financial Inc.在第二季度购买了 aTyr Pharma 的股份，价值约 63,000 美元。最后，Oxford Asset Management LLP 在第二季度购买了 aTyr Pharma 的股份，价值约 70,000 美元。对冲基金和其他机构投资者持有公司 61.72% 的股票。</p>
<h2>aTyr Pharma 股票表现</h2>
<p>ATYR 股票周一开盘价为 0.71 美元。aTyr Pharma 的 52 周低点为 0.64 美元，52 周高点为 7.29 美元。该公司的市值为 6944 万美元，市盈率为-0.85，贝塔值为 0.60。该公司的 50 日移动平均价格为 0.74 美元，200 日移动平均价格为 2.49 美元。</p>
<p>aTyr Pharma (NASDAQ:ATYR - 获取免费报告) 最近于 11 月 6 日宣布了季度财报。公司报告季度每股收益为（0.26 美元），低于分析师一致预期的（0.20 美元）6 美分。该季度的收入为 19 万美元，而一致预期为 91 万美元。整体来看，股票分析师预测 aTyr Pharma 在本年度将发布-0.91 的每股收益。</p>
<h2>华尔街分析师看法</h2>
<p>另外，Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 aTyr Pharma 股票的 “卖出（d-）” 评级。一位分析师给予该股票买入评级，六位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，平均目标价格为 23.25 美元。</p>
<p><strong>查看我们对 ATYR 的最新分析</strong></p>
<h2>关于 aTyr Pharma</h2>
<p>(获取免费报告)</p>
<p>aTyr Pharma, Inc 是一家临床阶段的生物技术公司，专注于发现和开发调节细胞外基质和免疫通路的新型蛋白质疗法。公司总部位于加利福尼亚州圣地亚哥，利用其专有的细胞外调节®平台，识别和优化生物治疗候选药物，以治疗罕见和严重疾病，包括肺肉芽肿病、肌肉萎缩症和实体肿瘤。</p>
<p>公司的研究工作集中在利用细胞外蛋白质调节组织重塑、细胞粘附和免疫信号传导。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票比 aTyr Pharma 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 aTyr Pharma 吗？</h2>
<p>在您考虑 aTyr Pharma 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 aTyr Pharma 并不在名单上。</p>
<p>虽然 aTyr Pharma 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LIFE

<p>aTyr Pharma, Inc.（纳斯达克代码：ATYR）在空头头寸方面经历了显著下降，截至 12 月 31 日下降了 17.7%，降至 25,013,857 股。该公司约有 26.5% 的股票被做空，覆盖天数比率为 11.1 天。对冲基金增加了其持仓，持有 61.72% 的股票。该公司的股票开盘价为 0.71 美元，市值为 6944 万美元。分析师对该股票给予持有评级，平均目标价为 23.25 美元</p>

<p>aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 25,013,857 shares, a drop of 17.7% from the December 15th total of 30,385,566 shares. Based on an average daily volume of 2,246,751 shares, the short-interest ratio is currently 11.1 days. Approximately 26.5% of the company's shares are short sold. Approximately 26.5% of the company's shares are short sold. Based on an average daily volume of 2,246,751 shares, the short-interest ratio is currently 11.1 days.</p>
<div class="lb-trans"><p>aTyr Pharma, Inc. (NASDAQ:ATYR - 获取免费报告) 在 12 月份经历了显著的空头头寸下降。截至 12 月 31 日，空头头寸总计为 25,013,857 股，比 12 月 15 日的 30,385,566 股下降了 17.7%。根据平均每日交易量 2,246,751 股，目前的空头头寸比率为 11.1 天。大约 26.5% 的公司股份被做空。</p>
</div><h2>Hedge Funds Weigh In On aTyr Pharma</h2>
<div class="lb-trans"><h2>对 aTyr Pharma 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new position in aTyr Pharma in the second quarter worth about $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of aTyr Pharma during the 2nd quarter worth approximately $45,000. Legal &amp; General Group Plc bought a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $49,000. Prudential Financial Inc. bought a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $63,000. Finally, Oxford Asset Management LLP purchased a new position in shares of aTyr Pharma in the 2nd quarter valued at approximately $70,000. Hedge funds and other institutional investors own 61.72% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对该股票的持有。加利福尼亚州教师退休系统在第二季度购买了 aTyr Pharma 的新头寸，价值约 28,000 美元。Ameritas Investment Partners Inc.在第二季度购买了 aTyr Pharma 的股份，价值约 45,000 美元。Legal &amp; General Group Plc 在第二季度购买了 aTyr Pharma 的股份，价值约 49,000 美元。Prudential Financial Inc.在第二季度购买了 aTyr Pharma 的股份，价值约 63,000 美元。最后，Oxford Asset Management LLP 在第二季度购买了 aTyr Pharma 的股份，价值约 70,000 美元。对冲基金和其他机构投资者持有公司 61.72% 的股票。</p>
</div><h2>aTyr Pharma Stock Performance</h2>
<div class="lb-trans"><h2>aTyr Pharma 股票表现</h2>
</div><p>Shares of ATYR stock opened at $0.71 on Monday. aTyr Pharma has a fifty-two week low of $0.64 and a fifty-two week high of $7.29. The firm has a market cap of $69.44 million, a P/E ratio of -0.85 and a beta of 0.60. The business's 50 day moving average price is $0.74 and its 200-day moving average price is $2.49.</p>
<div class="lb-trans"><p>ATYR 股票周一开盘价为 0.71 美元。aTyr Pharma 的 52 周低点为 0.64 美元，52 周高点为 7.29 美元。该公司的市值为 6944 万美元，市盈率为-0.85，贝塔值为 0.60。该公司的 50 日移动平均价格为 0.74 美元，200 日移动平均价格为 2.49 美元。</p>
</div><p>aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.06). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.91 million. As a group, equities analysts predict that aTyr Pharma will post -0.91 EPS for the current year.</p>
<div class="lb-trans"><p>aTyr Pharma (NASDAQ:ATYR - 获取免费报告) 最近于 11 月 6 日宣布了季度财报。公司报告季度每股收益为（0.26 美元），低于分析师一致预期的（0.20 美元）6 美分。该季度的收入为 19 万美元，而一致预期为 91 万美元。整体来看，股票分析师预测 aTyr Pharma 在本年度将发布-0.91 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师看法</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of aTyr Pharma in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of &#34;Hold&#34; and an average price target of $23.25.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 aTyr Pharma 股票的 “卖出（d-）” 评级。一位分析师给予该股票买入评级，六位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，平均目标价格为 23.25 美元。</p>
</div><p><strong>View Our Latest Analysis on ATYR</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ATYR 的最新分析</strong></p>
</div><h2>About aTyr Pharma</h2>
<div class="lb-trans"><h2>关于 aTyr Pharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.</p>
<div class="lb-trans"><p>aTyr Pharma, Inc 是一家临床阶段的生物技术公司，专注于发现和开发调节细胞外基质和免疫通路的新型蛋白质疗法。公司总部位于加利福尼亚州圣地亚哥，利用其专有的细胞外调节®平台，识别和优化生物治疗候选药物，以治疗罕见和严重疾病，包括肺肉芽肿病、肌肉萎缩症和实体肿瘤。</p>
</div><p>The company's research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.</p>
<div class="lb-trans"><p>公司的研究工作集中在利用细胞外蛋白质调节组织重塑、细胞粘附和免疫信号传导。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than aTyr Pharma</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 aTyr Pharma 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in aTyr Pharma Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 aTyr Pharma 吗？</h2>
</div><p>Before you consider aTyr Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 aTyr Pharma 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 aTyr Pharma 并不在名单上。</p>
</div><p>While aTyr Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 aTyr Pharma 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

aTyr Pharma, Inc.（纳斯达克股票代码：ATYR）空头头寸大幅减少